The approval is supported by data from a phase 3 study that compared the efficacy, safety, pharmacokinetics and immunogenicity of Riabni to rituximab reference products.
A study investigated if observing positive drug effects on pain and mobility in another patient increases pain reduction and functional capacity in other patients.
Presenting at AHS 2022, researchers assessed the efficacy of a 1-year treatment period with ubrogepant 50 or 100 mg in patients with migraine attacks with mild and moderate or severe pain.
Presenting at AHS 2022, researchers evaluated the real-world effectiveness of ubrogepant in combination with onabotulinumtoxinA to treat breakthrough migraine.
The USPSTF recommends against the use of beta carotene or vitamin E for prevention of CVD or cancer and finds that the evidence is insufficient for ascertaining the benefits and harms of multivitamin use.
This systematic review and Bayesian meta-analysis evaluated the relative efficacy of 18 oral pharmacotherapeutic interventions for diabetic peripheral neuropathy.